Literature DB >> 10720436

Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype.

P J Waters1, M A Parniak, B R Akerman, C R Scriver.   

Abstract

Missense mutations account for 48% of all reported human disease-causing alleles. Since few are predicted to ablate directly an enzyme's catalytic site or other functionally important amino acid residues, how do most missense mutations cause loss of function and lead to disease? The classic monogenic phenotype hyperphenylalaninemia (HPA), manifesting notably as phenylketonuria (PKU), where missense mutations in the PAH gene compose 60% of the alleles impairing phenylalanine hydroxylase (PAH) function, allows us to examine this question. Here we characterize four PKU-associated PAH mutations (F39L, K42I, L48S, I65T), each changing an amino acid distant from the enzyme active site. Using three complementary in vitro protein expression systems, and 3D-structural localization, we demonstrate a common mechanism. PAH protein folding is affected, causing altered oligomerization and accelerated proteolytic degradation, leading to reduced cellular levels of this cytosolic protein. Enzyme specific activity and kinetic properties are not adversely affected, implying that the only way these mutations reduce enzyme activity within cells in vivo is by producing structural changes which provoke the cell to destroy the aberrant protein. The F39L, L48S, and I65T PAH mutations were selected because each is associated with a spectrum of in vivo HPA among patients. Our in vitro data suggest that interindividual differences in cellular handling of the mutant, but active, PAH proteins will contribute to the observed variability of phenotypic severity. PKU thus supports a newly emerging paradigm both for mechanism whereby missense mutations cause genetic disease and for potential modulation of a disease phenotype. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720436     DOI: 10.1006/mgme.2000.2965

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  16 in total

Review 1.  The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders.

Authors:  N Gregersen; P Bross; B S Andrese; C B Pedersen; T J Corydon; L Bolund
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

Review 2.  Protein misfolding, aggregation, and degradation in disease.

Authors:  Niels Gregersen; Lars Bolund; Peter Bross
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

3.  Missense mutations in the N-terminal domain of human phenylalanine hydroxylase interfere with binding of regulatory phenylalanine.

Authors:  T Gjetting; M Petersen; P Guldberg; F Güttler
Journal:  Am J Hum Genet       Date:  2001-04-20       Impact factor: 11.025

4.  Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?

Authors:  Christineh N Sarkissian; Alejandra Gamez; Patrick Scott; Jerome Dauvillier; Alejandro Dorenbaum; Charles R Scriver; Raymond C Stevens
Journal:  JIMD Rep       Date:  2011-12-06

Review 5.  Garrod's foresight; our hindsight.

Authors:  C R Scriver
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

6.  Folding dynamics of phenylalanine hydroxylase depends on the enzyme's metallation state: the native metal, iron, protects against aggregate intermediates.

Authors:  Aristobulo Loaiza; Judith A Ronau; Alexander Ribbe; Lia Stanciu; John W Burgner; Lake N Paul; Mahdi M Abu-Omar
Journal:  Eur Biophys J       Date:  2011-06-07       Impact factor: 1.733

7.  The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.

Authors:  Maja Stojiljkovic; Belén Pérez; Lourdes R Desviat; Cristina Aguado; Magdalena Ugarte; Sonja Pavlovic
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

Review 8.  On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases.

Authors:  Subhashchandra Naik; Na Zhang; Phillip Gao; Mark T Fisher
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

9.  Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases.

Authors:  Angel L Pey; Francois Stricher; Luis Serrano; Aurora Martinez
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

10.  Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.

Authors:  Søren W Gersting; Kristina F Kemter; Michael Staudigl; Dunja D Messing; Marta K Danecka; Florian B Lagler; Christian P Sommerhoff; Adelbert A Roscher; Ania C Muntau
Journal:  Am J Hum Genet       Date:  2008-06-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.